NL297170A
(pt)
|
1963-04-04 |
1900-01-01 |
|
|
US3558618A
(en)
|
1968-04-01 |
1971-01-26 |
Dow Chemical Co |
Novel 4h-pyrazino(1,2-a)pyrimidine-4-ones
|
GB1383409A
(en)
|
1972-09-09 |
1974-02-12 |
Pfizer Ltd |
Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them
|
US4122274A
(en)
|
1977-05-25 |
1978-10-24 |
Bristol-Myers Company |
3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
|
JPS56150091A
(en)
|
1980-03-28 |
1981-11-20 |
Janssen Pharmaceutica Nv |
3-(1-piperidinylalkyl)-4h-pyrido(1,2-a)pyrimidine- 4-one derivative and its manufacture
|
US4342870A
(en)
|
1980-03-28 |
1982-08-03 |
Janssen Pharmaceutica N.V. |
Novel 3-(1-piperidinylalkyl)-4H-pyrido[1,2-a]pyrimidin-4-one derivatives
|
FR2567518B1
(fr)
*
|
1984-07-11 |
1987-11-13 |
Sanofi Sa |
Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
|
US5089633A
(en)
|
1987-04-28 |
1992-02-18 |
Georgia Tech Research Corporation |
Substituted isocoumarins
|
US5599816A
(en)
|
1990-05-02 |
1997-02-04 |
Abbott Laboratories |
Quinolizinone type compounds
|
AU4231293A
(en)
|
1992-05-13 |
1993-12-13 |
E.I. Du Pont De Nemours And Company |
Substituted pyrido(1,2-A)pyrimidinone derivatives as fungicides
|
AU6786594A
(en)
|
1993-05-11 |
1994-12-12 |
University Of North Carolina At Chapel Hill, The |
Antisense oligonucleotides which combat aberrant splicing and methods of using the same
|
WO1996039407A1
(en)
|
1995-06-06 |
1996-12-12 |
Abbott Laboratories |
Quinolizinone type compounds
|
US5916916A
(en)
|
1996-10-10 |
1999-06-29 |
Eli Lilly And Company |
1-aryloxy-2-arylnaphthyl compounds, intermediates, compositions, and methods
|
US5869500A
(en)
|
1996-12-13 |
1999-02-09 |
Hoffmann-La Roche Inc. |
Pyridone compounds useful in treating Alzheimer's disease
|
CA2269561C
(en)
|
1998-04-22 |
2007-06-05 |
Dainippon Ink And Chemicals, Inc. |
Naphthalene derivative and liquid crystal composition comprising the same
|
AU5991699A
(en)
|
1998-09-21 |
2000-04-10 |
Biochem Pharma Inc. |
Quinolizinones as integrin inhibitors
|
US6172216B1
(en)
|
1998-10-07 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of BCL-X expression
|
US6210892B1
(en)
|
1998-10-07 |
2001-04-03 |
Isis Pharmaceuticals, Inc. |
Alteration of cellular behavior by antisense modulation of mRNA processing
|
US6214986B1
(en)
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
AU7961100A
(en)
|
1999-10-28 |
2001-05-08 |
Daiichi Pharmaceutical Co., Ltd. |
Drug discharge pump inhibitors
|
AU2001230426C1
(en)
|
2000-01-24 |
2006-06-22 |
Astrazeneca Ab |
Therapeutic morpholino-substituted compounds
|
AU2002232536A1
(en)
|
2000-11-09 |
2002-05-21 |
Cold Spring Harbor Laboratory |
Chimeric molecules to modulate gene expression
|
US6774134B2
(en)
|
2000-12-20 |
2004-08-10 |
Bristol-Myers Squibb Company |
Heterocyclic substituted 2-methyl-benzimidazole antiviral agents
|
PT1355905E
(pt)
|
2000-12-21 |
2007-05-31 |
Vertex Pharma |
Compostos de pirazole úteis como inibidores de proteínaquinase
|
EP1389463A4
(en)
|
2001-04-26 |
2008-09-17 |
Daiichi Seiyaku Co |
MEDICAMENT FOR INHIBITING A DRUG REMOVAL PUMP
|
US20030199526A1
(en)
|
2001-12-07 |
2003-10-23 |
Deborah Choquette |
Pyrimidine-based compounds useful as GSK-3 inhibitors
|
GB0205281D0
(en)
|
2002-03-06 |
2002-04-17 |
Novartis Ag |
Organic compounds
|
CA2493458A1
(en)
|
2002-07-24 |
2004-01-29 |
Ptc Therapeutics, Inc. |
Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
|
US7423133B2
(en)
|
2002-08-23 |
2008-09-09 |
The Board Of Trustees Of The Leland Stanford Junior University |
Fluorescent glycosides and methods for their use
|
US7220741B2
(en)
|
2002-09-30 |
2007-05-22 |
Neurosearch A/S |
1,4-diazabicycloalkane derivatives, their preparation and use
|
US20070078144A1
(en)
|
2003-01-29 |
2007-04-05 |
Stockwell Brent R |
Agents for treating neurodegenerative diseases
|
DE602004025698D1
(de)
|
2003-06-20 |
2010-04-08 |
Novartis Vaccines & Diagnostic |
PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS
|
GB0315494D0
(en)
*
|
2003-07-02 |
2003-08-06 |
Biofocus Plc |
Compounds which bind to the active site of protein kinase enzymes
|
RU2355687C2
(ru)
|
2003-08-01 |
2009-05-20 |
Дженелэбс Текнолоджиз, Инк |
Бициклические производные имидазола в качестве средства против вирусов семейства flaviviridae
|
US7160888B2
(en)
|
2003-08-22 |
2007-01-09 |
Warner Lambert Company Llc |
[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
|
US20050074801A1
(en)
|
2003-09-09 |
2005-04-07 |
Monia Brett P. |
Chimeric oligomeric compounds comprising alternating regions of northern and southern conformational geometry
|
US7655657B2
(en)
|
2003-12-22 |
2010-02-02 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
US20050137203A1
(en)
*
|
2003-12-22 |
2005-06-23 |
Jianguo Ji |
3-quinuclidinyl amino-substituted biaryl derivatives
|
US20050245531A1
(en)
|
2003-12-22 |
2005-11-03 |
Abbott Laboratories |
Fused bicycloheterocycle substituted quinuclidine derivatives
|
US7309699B2
(en)
*
|
2003-12-22 |
2007-12-18 |
Abbott Laboratories |
3-Quinuclidinyl amino-substituted biaryl derivatives
|
ES2360222T3
(es)
|
2003-12-24 |
2011-06-02 |
Biota Scientific Management Pty. Ltd. |
Agentes policíclicos para el tratamiento de infecciones respiratorias por virus sincicial.
|
SE0400184D0
(sv)
|
2004-01-30 |
2004-01-30 |
Fyrkloevern Scandinavia Ab |
New therapeutical use
|
TW200536830A
(en)
|
2004-02-06 |
2005-11-16 |
Chugai Pharmaceutical Co Ltd |
1-(2H)-isoquinolone derivative
|
CA2557852A1
(en)
|
2004-04-08 |
2005-10-27 |
Neurogen Corporation |
Substituted cinnolin-4-ylamines
|
ES2292130T3
(es)
|
2004-05-04 |
2008-03-01 |
Warner-Lambert Company Llc |
Pirido(2,3-d)pirimidin-7-onas pirrolil-sustituidas y derivados de las mismas como agentes terapeuticos.
|
US7399767B2
(en)
|
2005-01-21 |
2008-07-15 |
Ortho-Mcneil Pharmaceutical, Inc. |
Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors
|
US7879992B2
(en)
|
2005-01-31 |
2011-02-01 |
Isis Pharmaceuticals, Inc. |
Modification of MyD88 splicing using modified oligonucleotides
|
GB0501999D0
(en)
|
2005-02-01 |
2005-03-09 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
JP2006219453A
(ja)
|
2005-02-14 |
2006-08-24 |
Tokyo Univ Of Pharmacy & Life Science |
キノリン環を母核とする金属識別型二波長性蛍光分子
|
US7563601B1
(en)
|
2005-06-01 |
2009-07-21 |
City Of Hope |
Artificial riboswitch for controlling pre-mRNA splicing
|
WO2006138418A2
(en)
|
2005-06-14 |
2006-12-28 |
President And Fellows Of Harvard College |
Improvement of cognitive performance with sirtuin activators
|
CN103110635A
(zh)
|
2005-07-04 |
2013-05-22 |
海波因特制药有限责任公司 |
组胺h3受体拮抗剂
|
US7473784B2
(en)
|
2005-08-01 |
2009-01-06 |
Bristol-Myers Squibb Company |
Benzothiazole and azabenzothiazole compounds useful as kinase inhibitors
|
US8258109B2
(en)
|
2005-10-20 |
2012-09-04 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for modulation of LMNA expression
|
EP2535413A3
(en)
|
2005-11-10 |
2016-04-13 |
Roche Innovation Center Copenhagen A/S |
Splice switching oligomers for the TNF superfamily receptors and their use in treatment of disease
|
ATE473978T1
(de)
|
2005-12-06 |
2010-07-15 |
Neurosearch As |
Neue diazabicyclische arylderivate und medizinische verwendung dafür
|
WO2007071055A1
(en)
|
2005-12-21 |
2007-06-28 |
Painceptor Pharma Corporation |
Compositions and methods for modulating gated ion channels
|
AU2007210038B2
(en)
|
2006-01-26 |
2013-01-10 |
Ionis Pharmaceuticals, Inc. |
Compositions and their uses directed to huntingtin
|
EP2388328A1
(en)
|
2006-01-27 |
2011-11-23 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for the use in modulation of micrornas
|
AR059339A1
(es)
|
2006-02-09 |
2008-03-26 |
Chugai Pharmaceutical Co Ltd |
Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene
|
US8110681B2
(en)
|
2006-03-17 |
2012-02-07 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Compounds for the treatment of spinal muscular atrophy and other uses
|
EA015569B1
(ru)
|
2006-03-28 |
2011-10-31 |
ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи |
Бензотиазолы, обладающие антагонистической активностью по отношению к h3-рецептору гистамина, и фармацевтические композиции, включающие эти соединения
|
WO2007130383A2
(en)
|
2006-04-28 |
2007-11-15 |
Northwestern University |
Compositions and treatments using pyridazine compounds and secretases
|
US20080247964A1
(en)
|
2006-05-08 |
2008-10-09 |
Yuelian Xu |
Substituted azaspiro derivatives
|
TW200812588A
(en)
|
2006-05-15 |
2008-03-16 |
Neurogen Corp |
CRF1 receptor ligands comprising heteroaryl fused bicycles
|
JP2009537599A
(ja)
|
2006-05-23 |
2009-10-29 |
ノイロサーチ アクティーゼルスカブ |
新規8,10−ジアザ−ビシクロ[4.3.1]デカン誘導体及びそれらの医学的使用
|
AU2007275682B2
(en)
|
2006-07-20 |
2012-05-17 |
Amgen Inc. |
Substituted pyridone compounds and methods of use
|
US8337941B2
(en)
|
2006-07-27 |
2012-12-25 |
The Trustees Of Columbia University In The City Of New York |
Fluorescent substrates for monoamine transporters as optical false neurotransmitters
|
ES2394971T3
(es)
|
2006-08-03 |
2013-02-07 |
Rottapharm S.P.A. |
Derivados de quinolinas y 6-1H-imidazo-quinazolina, agentes antiinflamatorios y analgésicos potentes nuevos
|
US20100029685A1
(en)
|
2006-10-25 |
2010-02-04 |
Neurosearch A/S |
Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
|
US8314119B2
(en)
|
2006-11-06 |
2012-11-20 |
Abbvie Inc. |
Azaadamantane derivatives and methods of use
|
CA2673183C
(en)
|
2006-12-22 |
2014-06-10 |
Eric Dale Jones |
Bicyclic pyrimidinones and uses thereof
|
WO2008083226A2
(en)
|
2006-12-28 |
2008-07-10 |
Navinta Llc |
Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
|
FR2914188B1
(fr)
|
2007-03-28 |
2012-06-22 |
Trophos |
Nouvelle composition a base d'oxime de cholest-4-en-3-one
|
EP2014656A3
(en)
|
2007-06-11 |
2011-08-24 |
High Point Pharmaceuticals, LLC |
New heteocyclic h3 antagonists
|
CN101878219B
(zh)
|
2007-09-27 |
2014-04-02 |
西班牙国家癌症研究中心 |
用于作为蛋白激酶抑制剂使用的咪唑并噻二唑类
|
EP2215074B1
(en)
|
2007-09-27 |
2014-02-19 |
The United States of America, as Represented by the Secretary, Department of Health and Human Services |
Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
|
US8153813B2
(en)
|
2007-12-20 |
2012-04-10 |
Abbott Laboratories |
Benzothiazole and benzooxazole derivatives and methods of use
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
WO2009126635A1
(en)
|
2008-04-09 |
2009-10-15 |
Abbott Laboratories |
2-amino-benzothiazole derivates useful as inhibitors of rock kinases
|
US20090264433A1
(en)
*
|
2008-04-21 |
2009-10-22 |
Institute For Oneworld Health |
Compounds, Compositions and Methods Comprising Triazine Derivatives
|
US8633019B2
(en)
|
2008-05-27 |
2014-01-21 |
Ptc Therapeutics, Inc. |
Methods for treating spinal muscular atrophy
|
WO2009152868A1
(en)
|
2008-06-20 |
2009-12-23 |
Rottapharm S.P.A. |
6-1h-imidazo-quinazoline and quinolines derivatives, new mao inhibitors and imidazoline receptor ligands
|
EP2138493A1
(en)
|
2008-06-26 |
2009-12-30 |
Sanofi-Aventis |
Substituted pyrimidone derivatives
|
WO2010000032A1
(en)
|
2008-07-02 |
2010-01-07 |
Avexa Limited |
Compounds having antiviral properties
|
WO2010019236A1
(en)
|
2008-08-13 |
2010-02-18 |
Ptc Therapeutics, Inc |
Methods for treating spinal muscular atrophy
|
WO2010024903A1
(en)
|
2008-08-29 |
2010-03-04 |
Yangbo Feng |
BENZO[d]OXAZOLES AND BENZO[d]THIAZOLES AS KINASE INHIBITORS
|
WO2010045303A2
(en)
|
2008-10-16 |
2010-04-22 |
Schering Corporation |
Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof
|
GB2465405A
(en)
|
2008-11-10 |
2010-05-19 |
Univ Basel |
Triazine, pyrimidine and pyridine analogues and their use in therapy
|
WO2010071819A1
(en)
|
2008-12-19 |
2010-06-24 |
Schering Corporation |
Bicyclic heterocyclic derivatives and methods of use thereof
|
CN102388043A
(zh)
|
2009-02-11 |
2012-03-21 |
桑诺维恩药品公司 |
组胺h3反相激动剂和拮抗剂及其使用方法
|
FR2945289A1
(fr)
|
2009-05-11 |
2010-11-12 |
Sanofi Aventis |
Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo°2,1-b! °1,3,4!thiadiazole, leur preparation et leur application en therapeutique
|
SG176921A1
(en)
|
2009-06-19 |
2012-01-30 |
Abbott Lab |
Diazahomoadamantane derivatives and methods of use thereof
|
ES2772825T3
(es)
|
2009-09-11 |
2020-07-08 |
Ionis Pharmaceuticals Inc |
Modulación de la expresión de huntingtina
|
WO2011050245A1
(en)
|
2009-10-23 |
2011-04-28 |
Yangbo Feng |
Bicyclic heteroaryls as kinase inhibitors
|
US20150018301A1
(en)
|
2009-11-06 |
2015-01-15 |
The Johns Hopkins University |
LRRK-2-Mediated Neuronal Toxicity
|
US8754220B2
(en)
|
2009-11-20 |
2014-06-17 |
Merck Sharp & Dohme Corp. |
Quinolizidinone carboxamide M1 receptor positive allosteric modulators
|
KR20130088002A
(ko)
|
2010-01-13 |
2013-08-07 |
재단법인 한국파스퇴르연구소 |
항-감염성 피리도(1,2-a)피리미딘
|
EP2534248B1
(en)
|
2010-02-08 |
2018-08-29 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
EP3208347B1
(en)
|
2010-02-08 |
2019-08-14 |
Ionis Pharmaceuticals, Inc. |
Selective reduction of allelic variants
|
EP2536738A4
(en)
|
2010-02-08 |
2014-09-17 |
Isis Pharmaceuticals Inc |
METHODS AND COMPOSITIONS SUITABLE FOR THE TREATMENT OF CONDITIONS OR CONDITIONS IN RELATION TO THE EXPANSION OF REPETITIONS
|
WO2011149856A1
(en)
|
2010-05-24 |
2011-12-01 |
Presidio Pharmaceuticals, Inc. |
Inhibitors of hcv ns5a
|
DK3031920T3
(da)
|
2010-07-19 |
2019-10-14 |
Ionis Pharmaceuticals Inc |
Modulation af dystrofi myotonica-protein kinase (dmpk) ekspression
|
WO2012019106A2
(en)
|
2010-08-06 |
2012-02-09 |
Board Of Regents Of The University Of Nebraska |
Positive and negative modulators of nmda receptors
|
WO2012075393A2
(en)
|
2010-12-02 |
2012-06-07 |
President And Fellows Of Harvard College |
Activators of proteasomal degradation and uses thereof
|
CN102617548A
(zh)
|
2011-01-31 |
2012-08-01 |
北京赛林泰医药技术有限公司 |
作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
|
WO2012104823A2
(en)
|
2011-02-04 |
2012-08-09 |
Novartis Ag |
Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
|
EP2673361B1
(en)
|
2011-02-08 |
2016-04-13 |
Ionis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
US8703763B2
(en)
|
2011-03-02 |
2014-04-22 |
Hoffmann-La Roche Inc. |
Bridged piperidine derivatives
|
US9447075B2
(en)
|
2011-08-02 |
2016-09-20 |
The Brigham And Women's Hospital, Inc. |
Pyridazine derivatives as EAAT2 activators
|
WO2013022984A1
(en)
|
2011-08-11 |
2013-02-14 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
US8871756B2
(en)
|
2011-08-11 |
2014-10-28 |
Hoffmann-La Roche Inc. |
Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease
|
US20130046093A1
(en)
|
2011-08-18 |
2013-02-21 |
Korea Institute Of Science And Technology |
Pharmaceutical compositions for preventing or treating degenerative brain disease and method of screening the same
|
US9976138B2
(en)
|
2011-08-29 |
2018-05-22 |
Ionis Pharmaceuticals, Inc. |
Methods and compounds useful in conditions related to repeat expansion
|
US9662314B2
(en)
|
2011-10-21 |
2017-05-30 |
Tufts Medical Center, Inc. |
Compounds and methods for the treatment of muscular disease, and related screening methods
|
GB201119538D0
(en)
|
2011-11-10 |
2011-12-21 |
Viral Ltd |
Pharmaceutical compounds
|
CA2856334A1
(en)
|
2011-11-28 |
2013-06-06 |
Christina Hebach |
Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease
|
CA2861609C
(en)
|
2011-12-30 |
2021-02-16 |
Ptc Therapeutics, Inc. |
Compounds for treating spinal muscular atrophy
|
CN104203239B
(zh)
|
2012-01-26 |
2017-09-08 |
Ptc医疗公司 |
用于治疗脊髓性肌萎缩的化合物
|
KR102341596B1
(ko)
|
2012-02-10 |
2021-12-21 |
피티씨 테라퓨틱스, 인크. |
척수성 근위축증을 치료하기 위한 화합물
|
KR102099997B1
(ko)
|
2012-03-01 |
2020-04-13 |
피티씨 테라퓨틱스, 인크. |
척수성 근위축증을 치료하기 위한 화합물
|
BR112014023483B1
(pt)
|
2012-03-23 |
2022-05-10 |
Ptc Therapeutics, Inc |
Composto e seu uso, composição farmacêutica e seu uso
|
PL3459942T3
(pl)
|
2012-04-24 |
2021-10-11 |
Vertex Pharmaceuticals Incorporated |
Inhibitory DNA-PK
|
US9212209B2
(en)
|
2012-07-13 |
2015-12-15 |
Indiana University Research And Technology Corporation |
Screening methods for spinal muscular atrophy
|
MY174339A
(en)
|
2012-08-13 |
2020-04-09 |
Novartis Ag |
1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
|
WO2014059341A2
(en)
|
2012-10-12 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Antisense compounds and uses thereof
|
WO2014059356A2
(en)
|
2012-10-12 |
2014-04-17 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
JP6291502B2
(ja)
|
2012-10-25 |
2018-03-14 |
アッシャー・サード・イニシアティブ・インコーポレイテッド |
ピラゾロピリダジンならびに網膜変性疾患およびアッシャー症候群に伴う聴力損失を処置するための方法
|
US9227976B2
(en)
|
2012-10-25 |
2016-01-05 |
Usher Iii Initiative, Inc. |
Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
|
JP6255711B2
(ja)
|
2012-11-01 |
2018-01-10 |
株式会社リコー |
エレクトロクロミック化合物、エレクトロクロミック組成物及び表示素子
|
US9040712B2
(en)
|
2013-01-23 |
2015-05-26 |
Novartis Ag |
Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
|
CA2899924A1
(en)
|
2013-02-04 |
2014-08-07 |
Isis Pharmaceuticals, Inc. |
Selective antisense compounds and uses thereof
|
AU2014224975B2
(en)
|
2013-03-05 |
2017-09-14 |
Merck Patent Gmbh |
Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer
|
WO2014184163A1
(en)
|
2013-05-14 |
2014-11-20 |
F. Hoffmann-La Roche Ag |
Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection
|
AR096684A1
(es)
|
2013-06-25 |
2016-01-27 |
Ptc Therapeutics Inc |
Compuestos para tratar atrofia muscular espinal
|
ES2917979T3
(es)
|
2013-07-31 |
2022-07-12 |
Novartis Ag |
Derivados de Piridazina 1,4-disustituidos y su uso para tratar afecciones relacionadas con la deficiencia de SMN
|
KR20160045063A
(ko)
|
2013-08-19 |
2016-04-26 |
에프. 호프만-라 로슈 아게 |
스크리닝 방법
|
WO2015095446A1
(en)
|
2013-12-19 |
2015-06-25 |
Ptc Therapeutics, Inc. |
Methods for modulating the amount of rna transcripts
|
WO2015095449A1
(en)
|
2013-12-19 |
2015-06-25 |
Ptc Therapeutics, Inc. |
Methods for modulating the amount rna transcripts
|
US10195202B2
(en)
|
2013-12-19 |
2019-02-05 |
Ptc Therapeutics, Inc. |
Methods for modulating the amount of RNA transcripts
|
MY193116A
(en)
|
2014-01-16 |
2022-09-26 |
Wave Life Sciences Ltd |
Chiral design
|
EP3094629B1
(en)
|
2014-01-17 |
2018-08-22 |
Novartis AG |
1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
AR099134A1
(es)
|
2014-01-24 |
2016-06-29 |
Hoffmann La Roche |
Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina
|
ES2850999T3
(es)
*
|
2014-03-14 |
2021-09-02 |
Raqualia Pharma Inc |
Derivados de azaespiro como antagonistas de TRPM8
|
US10005745B2
(en)
|
2014-03-19 |
2018-06-26 |
The Regents Of The University Of California |
Amyloid targeting agents and methods of using the same
|
EA202090486A3
(ru)
|
2014-05-15 |
2020-08-31 |
Ф. Хоффманн-Ля Рош Аг |
Соединения для лечения спинальной мышечной атрофии
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
WO2015195811A2
(en)
|
2014-06-17 |
2015-12-23 |
Novozymes A/S |
Biological phosphorus removal from wastewater
|
EP3160967B1
(en)
|
2014-06-25 |
2019-05-08 |
F. Hoffmann-La Roche AG |
N-(imidazo[1,2-a]pyrazin-6-yl)-benzamide compounds for treating spinal muscular atrophy
|
JP2018500302A
(ja)
|
2014-12-02 |
2018-01-11 |
バイエル・クロップサイエンス・アクチェンゲゼルシャフト |
有害生物防除剤としての二環式化合物
|
ES2732023T3
(es)
|
2014-12-24 |
2019-11-20 |
Uniqure Ip Bv |
Supresión del gen de la huntingtina inducida por ARNi
|
EP3244891B9
(en)
|
2015-01-16 |
2022-11-16 |
The General Hospital Corporation |
Compounds for improving mrna splicing
|
EP3256126B1
(en)
|
2015-02-09 |
2024-03-27 |
F. Hoffmann-La Roche AG |
Compounds for the treatment of cancer
|
GB201502567D0
(en)
|
2015-02-16 |
2015-04-01 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
WO2016144351A1
(en)
|
2015-03-11 |
2016-09-15 |
E. I. Du Pont De Nemours And Company |
Heterocycle-substituted bicyclic azole pesticides
|
GB201506933D0
(en)
|
2015-04-23 |
2015-06-10 |
Sentinel Oncology Ltd |
Pharmaceutical compounds
|
WO2016184832A1
(en)
|
2015-05-20 |
2016-11-24 |
F. Hoffmann-La Roche Ag |
Compounds for treating spinal muscular atrophy
|
EP3310169B1
(en)
|
2015-05-30 |
2023-05-17 |
PTC Therapeutics, Inc. |
Methods for modulating rna splicing
|
MA43072A
(fr)
|
2015-07-22 |
2018-05-30 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
US10226448B2
(en)
|
2015-08-03 |
2019-03-12 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridines and therapeutic uses thereof
|
US9920032B2
(en)
|
2015-10-02 |
2018-03-20 |
Incyte Corporation |
Heterocyclic compounds useful as pim kinase inhibitors
|
JP2018533594A
(ja)
|
2015-11-12 |
2018-11-15 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
筋萎縮性側索硬化症を処置するための化合物
|
EP4360707A2
(en)
|
2015-11-12 |
2024-05-01 |
F. Hoffmann-La Roche AG |
Compositions for treating spinal muscular atrophy
|
US10383867B2
(en)
|
2015-11-28 |
2019-08-20 |
Russell Dahl |
Quinoline derivatives and their use for treating endoplasmic reticulum stress-related diseases and disorders
|
JP6872550B2
(ja)
|
2015-12-10 |
2021-05-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
架橋されたピペリジン誘導体
|
SG11201804915RA
(en)
*
|
2015-12-10 |
2018-07-30 |
Ptc Therapeutics Inc |
Methods for treating huntington's disease
|
US10526345B2
(en)
|
2016-04-08 |
2020-01-07 |
Mankind Pharma Ltd. |
Compounds as GPR119 agonists
|
AR108325A1
(es)
|
2016-04-27 |
2018-08-08 |
Samumed Llc |
Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
|
MA45270A
(fr)
|
2016-05-04 |
2017-11-09 |
Wave Life Sciences Ltd |
Compositions d'oligonucléotides et procédés associés
|
EP3463343B1
(en)
|
2016-05-31 |
2022-03-23 |
Board of Regents, The University of Texas System |
Heterocyclic inhibitors of ptpn11
|
US20190264267A1
(en)
|
2016-07-25 |
2019-08-29 |
Wave Life Sciences Ltd. |
Phasing
|
GB201616627D0
(en)
|
2016-09-30 |
2016-11-16 |
Mission Therapeutics Limited |
Novel compounds
|
TW201819386A
(zh)
|
2016-10-24 |
2018-06-01 |
美商傳達治療有限公司 |
Shp2磷酸酶抑制劑及其使用方法
|
WO2018187209A1
(en)
|
2017-04-03 |
2018-10-11 |
Acceleron Pharma Inc. |
Compositions and methods for treating spinal muscular atrophy
|
US11591336B2
(en)
|
2017-05-26 |
2023-02-28 |
D. E. Shaw Research, Llc |
Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors
|
KR20200033249A
(ko)
|
2017-06-05 |
2020-03-27 |
피티씨 테라퓨틱스, 인크. |
헌팅턴병 치료 화합물
|
BR112019027719A2
(pt)
|
2017-06-28 |
2020-07-28 |
Ptc Therapeutics, Inc. |
métodos para tratar a doença de huntington
|
EP3644996B1
(en)
|
2017-06-28 |
2023-07-26 |
PTC Therapeutics, Inc. |
Methods for treating huntington's disease
|
KR102636383B1
(ko)
|
2017-08-04 |
2024-02-14 |
스카이호크 테라퓨틱스, 인코포레이티드 |
스플라이싱을 조절하는 방법 및 조성물
|
EP3755699A1
(en)
|
2018-02-21 |
2020-12-30 |
Relay Therapeutics, Inc. |
Shp2 phosphatase inhibitors and methods of use thereof
|
CN112166110B
(zh)
|
2018-03-21 |
2023-08-11 |
传达治疗有限公司 |
Shp2磷酸酶抑制剂及其使用方法
|
EP3768680A1
(en)
|
2018-03-21 |
2021-01-27 |
Relay Therapeutics, Inc. |
Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof
|
EA202092001A1
(ru)
|
2018-03-27 |
2021-01-29 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Соединения для лечения болезни гентингтона
|
BR112020026545A2
(pt)
|
2018-06-27 |
2021-03-23 |
Ptc Therapeutics, Inc. |
Compostos heterocíclicos e de heteroarila para o tratamento da doença de huntington
|
US11685746B2
(en)
|
2018-06-27 |
2023-06-27 |
Ptc Therapeutics, Inc. |
Heteroaryl compounds for treating Huntington's disease
|
EA202092899A1
(ru)
|
2018-06-27 |
2021-05-14 |
ПиТиСи ТЕРАПЬЮТИКС, ИНК. |
Гетероарильные соединения для лечения болезни гентингтона
|
US20230227474A1
(en)
|
2019-03-15 |
2023-07-20 |
Skyhawk Therapeutics, Inc. |
Compositions and methods for correction of aberrant splicing
|
MX2021013854A
(es)
|
2019-05-13 |
2022-03-22 |
Ptc Therapeutics Inc |
Compuestos para tratar enfermedad de huntington.
|
WO2021007378A1
(en)
|
2019-07-11 |
2021-01-14 |
Ptc Therapeutics, Inc. |
Compounds for use in treating huntington's disease
|
WO2021084495A1
(en)
|
2019-11-01 |
2021-05-06 |
Novartis Ag |
The use of a splicing modulator for a treatment slowing progression of huntington's disease
|
AU2021254418A1
(en)
|
2020-04-09 |
2022-11-03 |
Ptc Therapeutics, Inc. |
Compounds for treating Huntington's disease
|
IL302839A
(en)
|
2020-11-12 |
2023-07-01 |
Ptc Therapeutics Inc |
A novel RNA transcript
|
WO2023009816A1
(en)
|
2021-07-30 |
2023-02-02 |
Ptc Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|